RxDoctor Payments Data

Elizabeth Belloli, MD

Pulmonary Disease · Ann Arbor, MINPI 1891923322

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (48.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by Boehringer Ingelheim at 58.9% of the total. 2025 is the largest year on record at $5,019, 3.1 times the $1,600 reported in 2020.

$11,241in general payments, 2019–2025

Across 11 payments — averaging $1021.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$7K
  • Boehringer Ingelheim International GmbH$3K
  • ANI Pharmaceuticals, Inc.$1K
  • United Therapeutics Corporation$146
$794,574in research payments, 2019–2025

Across 171 payments — averaging $4646.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • United Therapeutics Corporation$716K
  • Genentech, Inc.$57K
  • Boehringer Ingelheim$20K
  • Boehringer Ingelheim International GmbH$1K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$487
  • Boehringer Ingelheim Limited$393

What the payments were for

  • Consulting fees$5,47049%
  • Speaking & faculty fees$4,47640%
  • Travel & lodging$8938%
  • Food & beverage$4024%

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,241 in reported general payments places this provider in the 80th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan

Medicare billing

Part B allowed, 2024
$44,209
Medicare patients
279
Services billed
976

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate226$2,940,730
Pirfenidone165$326,872
EliquisApixaban45$39,868
Spiriva RespimatTiotropium Bromide32$21,169
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr35$18,734
Stiolto RespimatTiotropium Br/Olodaterol Hcl36$18,541
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate43$18,485
Breo ElliptaFluticasone/Vilanterol32$15,460
Everolimus13$13,065
Tacrolimus120$12,552
SymbicortBudesonide/Formoterol Fumarate29$11,360
Mycophenolate Mofetil86$10,345
Mycophenolic AcidMycophenolate Sodium29$8,370
Incruse ElliptaUmeclidinium Bromide11$8,278
BreynaBudesonide/Formoterol Fumarate26$6,475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$6,619$2,986,474307 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 463 pulmonary disease providers in Michigan.

Other pulmonary disease in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →